Lombard Odier Investment Managers

Everdrop GmbH, founded in 2019 and based in Munich, Germany, specializes in the manufacture of plastic-free cleaning products aimed at promoting sustainability in household cleaning. The company's offerings include vegan natural cosmetic products, packaged cleanser tablets that can be mixed at home, reusable spray bottles, and laundry detergent powder. By providing these eco-friendly alternatives, Everdrop enables consumers to maintain their households in a straightforward and environmentally conscious manner.

Isar Aerospace Technologies GmbH is a space technology company based in Munich, Germany, founded in 2018. The firm specializes in developing launch vehicles designed to provide low-cost and flexible access to space for small and medium payloads, particularly targeting satellite constellations. By utilizing advanced rocket engineering, environmentally friendly propellants, and innovative manufacturing techniques, Isar Aerospace aims to lower the entry barriers for companies seeking to deploy satellites. The company's focus on affordability and sustainability positions it as a key player in the growing market for satellite launch services.

Taurus Group SA is a Swiss financial services company founded in April 2018 and based in Geneva. The company provides platforms for trading, investing, and safeguarding digital assets. Its offerings include TAURUS TRADE, an online exchange and trading platform for digital assets; TAURUS INVEST, which delivers asset management and advisory services within the digital asset sector; and TAURUS PROTECT, a vault service designed for the secure storage of digital assets. Established by professionals with backgrounds in regulation, banking, asset management, and cybersecurity, Taurus aims to leverage blockchain technologies to enhance the financial landscape and integrate digital asset management with traditional financial practices.

TriArm Therapeutics is a cell therapy company formed by Panacea Venture with R&D operations in Germany, United States and Greater China region. The company focuses on the research and clinical transformation of CD19 CAR-T product using non-viral gene transfer technology, which greatly reduces the cost and time of cell therapy product preparation, enabling better tumor therapy outcome.

PrimaryBid Limited operates an online investment platform aimed at providing private investors with equitable access to placings, fundraisings, and IPOs of AIM-listed companies. Founded in 2012 and based in London, the platform allows individual investors to bid for new shares on their own terms, ensuring they transact simultaneously and at the same price as institutional investors. Through a long-term agreement with the London Stock Exchange, PrimaryBid has established the infrastructure necessary to connect retail investors directly with public companies during critical fundraising opportunities. The company also partners with firms like Shore Capital Group, finnCap, and Arden to enhance its offerings. By automating the aggregation of retail demand, PrimaryBid facilitates participation from a large pool of investors, enabling businesses across the Eurozone to access their discounted share issuances more effectively.

Simba Sleep is a London-based company that designs and manufactures a range of sleep products, primarily focusing on mattresses. Founded in 2015, the company offers innovative mattresses that combine thousands of lightweight comfort springs with precision-engineered foam to enhance sleep quality. Simba Sleep's product line includes mattresses, pillows, duvets, bedding, and bed bases, utilizing a unique four-layer cooling foam system supported by patented conical pocket springs. The company emphasizes the importance of sleep and aims to help customers achieve better rest. Products are available through select retail partnerships, such as John Lewis, as well as via online sales, with financing options provided for customers.

PrimaryBid Limited operates an online investment platform aimed at providing private investors with equitable access to placings, fundraisings, and IPOs of AIM-listed companies. Founded in 2012 and based in London, the platform allows individual investors to bid for new shares on their own terms, ensuring they transact simultaneously and at the same price as institutional investors. Through a long-term agreement with the London Stock Exchange, PrimaryBid has established the infrastructure necessary to connect retail investors directly with public companies during critical fundraising opportunities. The company also partners with firms like Shore Capital Group, finnCap, and Arden to enhance its offerings. By automating the aggregation of retail demand, PrimaryBid facilitates participation from a large pool of investors, enabling businesses across the Eurozone to access their discounted share issuances more effectively.

Attraqt Group plc is a technology company based in London that specializes in e-commerce solutions, focusing on site search, merchandising, and product recommendation systems. The company offers a Software as a Service (SaaS) platform that enables online retailers to enhance their customer experiences through personalized search, navigation, and merchandising tools. Attraqt serves a diverse range of sectors, including fashion, homeware, electronics, and B2B retail, and its core product, the Fredhopper Discovery Platform, supports retailers in creating relevant and engaging shopping experiences. The company also provides retail insights, technical expertise, and project management services to ensure customer success. With a presence in several countries, including the United Kingdom, France, and the Netherlands, Attraqt is committed to empowering over 240 leading retail brands globally.

Pieris Pharmaceuticals is a clinical-stage biopharmaceutical company based in Boston, Massachusetts, focused on discovering and developing anticalin-based therapeutics. Anticalins are low molecular-weight proteins derived from lipocalins, which are naturally occurring proteins in the human body. The company’s lead respiratory candidate, PRS-060, is in Phase I trials for asthma and other inflammatory diseases, while its lead immuno-oncology candidate, PRS-343, is also in Phase I trials targeting various cancers. Additionally, Pieris is advancing PRS-080, a treatment for functional iron deficiency in patients with chronic kidney disease, currently in Phase IIa trials, and PRS-344, a bispecific anticalin-antibody fusion protein in preclinical development for oncology. The company collaborates with several partners, including Les Laboratoires Servier, AstraZeneca, and Seattle Genetics, and has research collaborations with academic institutions such as the University of Pittsburgh. Founded in 2000, Pieris Pharmaceuticals aims to address critical medical needs through its innovative drug development approach.

Agensys is a biotechnology company focused on the research and development of therapeutic human monoclonal antibodies and antibody-drug conjugates specifically for cancer treatment. The company offers products aimed at addressing various tumors, including those associated with prostate, pancreatic, bladder, kidney, lung, and colon cancers. Founded in 1997 and based in Santa Monica, California, Agensys operates as a subsidiary of Astellas Pharma US, Inc. It is dedicated to providing innovative therapeutic solutions to improve patient outcomes in oncology.

Palatin Technologies, Inc. is a biopharmaceutical company focused on developing targeted receptor-specific therapeutics to address various medical conditions with significant unmet needs. The company's lead product, Vyleesi, is a melanocortin receptor agonist designed to treat premenopausal women with acquired, generalized hypoactive sexual desire disorder. In addition, Palatin is advancing several other drug candidates, including oral PL8177, a selective melanocortin receptor 1 agonist aimed at treating inflammatory bowel diseases, and systemic PL8177 for non-infectious uveitis and COVID-19. The company is also developing PL9643 for anti-inflammatory ocular conditions, particularly dry eye disease, and PL3994, a natriuretic peptide receptor-A agonist for cardiovascular issues. Furthermore, PL5028 is being explored as a treatment for cardiovascular and fibrotic diseases. Founded in 1986 and based in Cranbury, New Jersey, Palatin Technologies is committed to creating innovative therapies that address critical health challenges.

Agensys is a biotechnology company focused on the research and development of therapeutic human monoclonal antibodies and antibody-drug conjugates specifically for cancer treatment. The company offers products aimed at addressing various tumors, including those associated with prostate, pancreatic, bladder, kidney, lung, and colon cancers. Founded in 1997 and based in Santa Monica, California, Agensys operates as a subsidiary of Astellas Pharma US, Inc. It is dedicated to providing innovative therapeutic solutions to improve patient outcomes in oncology.

Hybrigenics Pharma is a bio-pharmaceutical company with a focus on research and development of new targets and therapies against cancer.Hybrigenics Pharma has stopped the development of inecalcitol, a vitamin D receptor agonist.Hybrigenics Pharma's research program investigates the action of enzymes called Deubiquitinating Enzymes (DUBs) in the recycling of onco-proteins and the potential activity of proprietary patented DUB inhibitors against various cancer indications.

AGY Therapeutics, Inc. is a biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative treatments for central nervous system (CNS) diseases. The company targets neurodegenerative diseases, CNS injuries, stroke, cognitive disorders, and schizophrenia, with a diverse pipeline that includes both clinical and preclinical programs. AGY has developed a proprietary platform for functional gene discovery, which aids in identifying and validating therapeutic targets that can modulate disease progression. Key programs in their pipeline include treatments for stroke, cognitive impairment, and schizophrenia, as well as various antibody and receptor therapies. Founded in 1998 and based in South San Francisco, California, AGY Therapeutics aims to address significant unmet medical needs in the CNS therapeutic landscape.

Fast Track: a completely new and comprehensive approach to the way clinical trials are managed. The company is assembling a creative and energetic staff of technical and medical professionals, an experienced management team, industry-specific advisory boards, and an active investor constituency - all aggressively focused on achieving their vision: to revolutionize the management of clinical trials.

Cytos is a public biopharmaceutical company focused on the development of targeted immunotherapies with a VLP B-cell vaccines platform and ongoing preclinical development programs based on the platform.

Illumina is a leading company in the field of genomics, specializing in tools and services for analyzing genetic material with applications in life sciences and clinical laboratories. Founded in 1998 in San Diego, California, by David R. Walt, Satnam Alag, Larry Bock, and John Stuelpnagel, Illumina primarily generates its revenue from sequencing instruments, consumables, and associated services, accounting for over 90% of its sales. The company’s high-throughput technology facilitates whole genome sequencing in humans and other organisms, while its lower throughput tools are designed for specific applications such as viral and cancer tumor screening. Additionally, Illumina offers microarrays for cost-effective genetic screening, which are used mainly in consumer and agricultural contexts. Through initiatives like Illumina Accelerator, the company fosters innovation by supporting startups with mentorship and access to essential resources, thereby contributing to advancements in personalized medicine and improving human health.

Agensys is a biotechnology company focused on the research and development of therapeutic human monoclonal antibodies and antibody-drug conjugates specifically for cancer treatment. The company offers products aimed at addressing various tumors, including those associated with prostate, pancreatic, bladder, kidney, lung, and colon cancers. Founded in 1997 and based in Santa Monica, California, Agensys operates as a subsidiary of Astellas Pharma US, Inc. It is dedicated to providing innovative therapeutic solutions to improve patient outcomes in oncology.

Ceptyr, Inc was founded to focus on developing drugs against protein tyrosine phosphatases (PTPs), a largely unexplored niche in pharmaceutical development.